Merck Continues Manufacturing Site Divestment With Sale Of Pavia, Italy, Factory
This article was originally published in The Pink Sheet Daily
Executive Summary
Italy strengthens future role in pharmaceutical manufacturing by the purchase of Merck & Co.’s high-profile Pavia facility by a local company.
You may also be interested in...
Evotec CEO: Growth Prospects Rely Heavily On Roche, Sanofi Deals
After disappearance last year of its drug hope DiaPep277 due to fraud, Germany’s Evotec is now looking to its Alzheimer’s MAO partnership with Roche and newly entered R&D alliance with Sanofi for future growth.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.